Loading
EDNRA (Endothelin-1 receptor) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Prostate cancer. This dossier gathers the 2 products (0 approved), 2 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Receptor for endothelin-1. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. The rank order of binding affinities for ET-A is: ET1 > ET2 >> ET3. Location: Cell membrane (UniProt). Locus 4q31.22-q31.23 (HGNC).
| Modality | Withdrawn or failed |
|---|---|
| Small molecule 2 |
| Trial | Setting | Result | Products | ||
|---|---|---|---|---|---|
SWOG S0421 NCT00134056 | 3 | Negative | Metastatic castration-resistant prostate cancer with bone metastases, stratified by progression type, baseline pain, extraskeletal metastases and bisphosphonate use: docetaxel 75 mg/m2 every 21 days with atrasentan 10 mg daily or placebo for up to 12 cycles, with co-primary endpoints of progression-free survival and overall survival | Median overall survival 17.8 against 17.6 months (hazard ratio 1.04, 95 percent confidence interval 0.90 to 1.19) and progression-free survival 9.2 against 9.1 months (1.02, 0.89 to 1.16); halted early for futility, and no difference in pain palliation. | |
ENTHUSE M1 NCT00554229 | 3 | Negative | Castration-resistant prostate cancer with bone metastases in men who were pain-free or mildly symptomatic: zibotentan 10 mg daily or placebo added to standard prostate cancer treatment, with overall survival as the primary endpoint | Median overall survival 24.5 against 22.5 months (hazard ratio 0.87, 95.2 percent confidence interval 0.69 to 1.10, p=0.240): not significant, with peripheral oedema in 44 percent and cardiac failure of any grade in 5.7 against 1.7 percent. |
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"EDNRA" OR ABSTRACT:"EDNRA" OR TITLE:"endothelin receptor type A" OR ABSTRACT:"endothelin receptor type A" OR TITLE:"Endothelin-1 receptor" OR ABSTRACT:"Endothelin-1 receptor" OR TITLE:"ET-A" OR ABSTRACT:"ET-A" OR TITLE:"ETA-R" OR ABSTRACT:"ETA-R" OR TITLE:"hET-AR" OR ABSTRACT:"hET-AR") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about EDNRA, not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/ednra.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/ednra.json. Licence CC BY-NC 4.0.